Drug
Zanubrutinib
Zanubrutinib: highest development phase Post-Market, developed by BeiGene, Genmab. 8 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- BeiGene, Genmab
Trials
| Drug | Phase | Indication |
|---|---|---|
| Zanubrutinib NCT07169331 | Post-Market | Waldenström's Macroglobulinemia |
| Zanubrutinib NCT03145064 | Phase 2 | Diffuse Large B-cell Lymphoma |
| Zanubrutinib NCT04382586 | Phase 2 | COVID-19 Pulmonary Complications |
| Zanubrutinib NCT06563596 | Phase 2 | Follicular Lymphoma |
| Zanubrutinib NCT03520920 | Phase 2 | Marginal Zone Lymphoma |
| Zanubrutinib NCT04436107 | Phase 1 | Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
| Zanubrutinib NCT04551963 | Phase 1 | B-cell Malignancies |
| Zanubrutinib NCT03465059 | Phase 1 | Hepatic Insufficiency & Healthy Subjects |
Latest
Follow Zanubrutinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.